Singapore markets closed

Straits Times Index
3,307.90
-6.15(-0.19%)
Nikkei
38,946.93
-122.75(-0.31%)
Hang Seng
19,220.62
-415.60(-2.12%)
FTSE 100
8,416.45
-7.75(-0.09%)
Bitcoin USD
69,876.66
+2,177.00(+3.22%)
CMC Crypto 200
1,526.32
+37.78(+2.54%)

UroGen Pharma Ltd. (0XOD.L)

LSE - LSE Delayed price. Currency in USD

Add to watchlist

13.01

+0.03

(+0.23%)

At close: 05:57PM BST

Loading interactive chart…

Simply Wall St.
UroGen Pharma First Quarter 2024 Earnings: Misses Expectations
UroGen Pharma ( NASDAQ:URGN ) First Quarter 2024 Results Key Financial Results Revenue: US$18.8m (up 9.2% from 1Q...
GuruFocus.com
UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
Insight into UroGen Pharma's First Quarter Financial Performance and Strategic Highlights
Business Wire
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
PRINCETON, N.J., May 13, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent developments.